Exp Clin Endocrinol Diabetes 2008; 116(6): 341-346
DOI: 10.1055/s-2007-1004566
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Multiple Relapses of Hyperthyroidism after Thyroid Surgeries in a Patient with Long Term Follow-up of Sporadic Non-autoimmune Hyperthyroidism

R. Bircan 2 , K. Miehle 1 , G. Mladenova 3 , R. Ivanova 4 , R. Ivanova 5 , A. Sarafova 4 , A.-M. Borissova 4 , J. Lüblinghoff 1 , R. Paschke 1
  • 1Department of Internal Medicine III, University of Leipzig, Germany
  • 2Department of Medical Biology, School of Medecine, Marmara University, Istanbul, Turkey
  • 3Pediatric Endocrinology Clinic, University Children's Hospital, Sofia, Bulgaria
  • 4Clinic of Thyroidology and Metabolic Bone Diseases, University Hospital of Endocrinology, Medical University Sofia, Sofia, Bulgaria
  • 5Laboratory of Pathomorphology and Cytopathology, University Hospital of Endocrinology, Medical University Sofia, Sofia, Bulgaria
Further Information

Publication History

received 17.08.2007 first decision 11.10.2007

accepted 03.12.2007

Publication Date:
05 June 2008 (online)

Abstract

Constitutively activating thyrotropin receptor (TSHR) germline mutations have been identified as a molecular cause of congenital hyperthyroidism. Patients with relapsing hyperthyroidism were previously treated with surgery and radioiodine. We report on a 22 year old male patient who was treated for his multiple relapses of hyperthyroidism by repeated subtotal thyroidectomies (STE). During the 22 years of follow-up, the patient developed several relapses of hyperthyroidism, four of them after thyroid surgeries. Sequencing of the TSHR gene revealed a gain-of-function mutation with an amino acid exchange of aspartate to tyrosine in codon 633 which is located in the sixth transmembrane domain of the TSH receptor. The absence of the mutation in all other family members identifies the patient's TSHR mutation as a sporadic germline mutation. In this patient, thyroid tissue growth and hyperthyroidism could repeatedly be controlled only for limited periods by near total thyroidectomy. Therefore, this case confirms that early combined treatment with near-total thyroidectomy plus radioiodine therapy seems to be the treatment of choice for patients with sporadic non-autoimmune hyperthyroidism.

References

  • 1 Borgel K, Pohlenz J, Koch HG, Bramswig JH. Long-term carbimazole treatment of neonatal nonautoimmune hyperthyroidism due to a new activating TSH receptor gene mutation (Ala428Val).  Horm Res. 2005;  64 203-208
  • 2 Claeysen S, Govaerts C, Lefort A, Van SJ, Costagliola S, Pardo L, Vassart G. A conserved Asn in TM7 of the thyrotropin receptor is a common requirement for activation by both mutations and its natural agonist.  FEBS Lett. 2002 April 24;  517 195-200
  • 3 Roux N de, Polak M, Couet J, Leger J, Czernichow P, Milgrom E, Misrahi M. A neomutation of the thyroid-stimulating hormone receptor in a severe neonatal hyperthyroidism.  J Clin Endocrinol Metab. 1996;  8 2023-2026
  • 4 Duprez L, Parma J, Costagliola S, Hermans J, Sande J Van, Dumont JE, Vassart G. Constitutive activation of the TSH receptor by spontaneous mutations affecting the N-terminal extracellular domain.  FEBS Lett. 1997;  409 469-474
  • 5 Esapa CT, Duprez L, Ludgate M, Mustafa MS, Kendall-Taylor P, Vassart G, Harris PE. A novel thyrotropin receptor mutation in an infant with severe thyrotoxicosis.  Thyroid. 1999;  9 1005-1010
  • 6 Fuhrer D, Lachmund P, Nebel IT, Paschke R. The thyrotropin receptor mutation database: update 2003.  Thyroid. 2003;  13 1123-1126
  • 7 Fuhrer D, Mix M, Wonerow P, Richter I, Willgerodt H, Paschke R. Variable phenotype associated with Ser505Asn-activating thyrotropin-receptor germline mutation.  Thyroid. 1999;  9 757-761
  • 8 Fuhrer D, Wonerow P, Willgerodt H, Paschke R. Identification of a new thyrotropin receptor germline mutation (Leu629Phe) in a family with neonatal onset of autosomal dominant nonautoimmune hyperthyroidism.  J Clin Endocrinol Metab. 1997;  82 4234-4238
  • 9 Gozu HI, Bircan R, Krohn K, Mueller S, Ekinci G, Yavuzer D, Sargin H, Sargin M, Orbay E, Cirakoglu B, Paschke R. A further germline variant in the extracellular domain of the TSH-receptor and reexamination of autosomal dominant non-autoimmune hyperthyroidism.  Eur J Endocrinol. 2007;  in revision
  • 10 Gozu HI, Bircan R, Krohn K, Muller S, Vural S, Gezen C, Sargin H, Yavuzer D, Sargin M, Cirakoglu B, Paschke R. Similar prevalence of somatic TSH receptor and Gsalpha mutations in toxic thyroid nodules in geographical regions with different iodine supply in Turkey.  Eur J Endocrinol. 2006;  155 535-545
  • 11 Gruters A, Schoneberg T, Biebermann H, Krude H, Krohn HP, Dralle H, Gudermann T. Severe congenital hyperthyroidism caused by a neo mutation in the extracellular portion of the thyrotropin receptor.  J Clin Endocrinol Metab. 1998;  83 1431-1436
  • 12 Ho SC, Sande J Van, Lefort A, Vassart G, Costagliola S. Effects of mutations involving the highly conserved S281HCC motif in the extracellular domain of the thyrotropin (TSH) receptor on TSH binding and constitutive activity.  Endocrinology. 2001;  142 2760-2767
  • 13 Holzapfel HP, Wonerow P, Petrykowski W von, Henschen M, Scherbaum WA, Pascke R. Sporadic congenital hyperthyroidism due to a spontaneous germline mutation in the thyrotropin receptor gene.  J Clin Endocrinol Metab. 1997;  82 3879-3884
  • 14 Jaeschke H, Neumann S, Kleinau G, Mueller S, Claus M, Krause G, Paschke R. An aromatic environment in the vicinity of serine 281 is a structural requirement for thyrotropin receptor function.  Endocrinology. 2006;  147 1753-1760
  • 15 Kopp P, Jameson JL, Roe TF. Congenital nonautoimmune hyperthyroidism in a nonidentical twin caused by a sporadic germ-line mutation in the thyrotropin receptor gene.  Thyroid. 1997;  7 765-769
  • 16 Kopp P, Sande J van, Parma J, Duprez L, Gerber H, Joss E, Jameson JL, Dumont JE, Vassart G. Brief report: Congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene.  N Engl J Med. 1995;  332 150-154
  • 17 Kosugi S, Shenker A, Mori T. Constitutive activation of cyclic AMP but not phosphatidylinositol signaling caused by four mutations in the 6th transmembrane helix of the human thyrotropin receptor.  FEBS Lett. 1994;  356 291-294
  • 18 Lavard L, Sehested A, Brock Jacobsen B, Muller J, Perrild H, Feldt-Rasmussen U, Parma J, Vassart G. Long-term follow-up of an infant with thyrotoxicosis due to germline mutation of the TSH receptor gene (Met453Thr).  Horm Res. 1999;  51 43-46
  • 19 Leclere J, Bene MC, Aubert V, Klein M, Pascal-Vigneron V, Weryha G, Faure G. Clinical consequences of activating germline point-mutations of the TSH receptor, the concept of toxic hyperplasia.  Horm Res. 1997;  47 158-162
  • 20 Nishihara E, Fukata S, Hishinuma A, Kudo T, Ohye H, Ito M, Kubota S, Amino N, Kuma K, Miyauchi A. Sporadic congenital hyperthyroidism due to a germline mutation in the thyrotropin receptor gene (Leu512Gln) in a japanese patient.  Endocr J. 2006;  53 735-740
  • 21 Parma J, Duprez L, Sande J Van, Hermans J, Rocmans P, Vliet G Van, Costagliola S, Rodien P, Dumont JE, Vassart G. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas.  J Clin Endocrinol Metab. 1997;  82 2695-2701
  • 22 Parma J, Sande J van, Swillens S, Tonacchera M, Dumont J, Vassart G. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: Identification of additional mutations activating both the cyclic adenosine 3′, 5′-monophosphate and inositol phosphate-Ca2+ cascades.  Mol Endocrinol. 1995;  9 725-733
  • 23 Porcellini A, Ciullo I, Laviola L, Amabile G, Fenzi G, Avvedimento VE. Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning adenomas. Rapid identification by fine needle aspiration biopsy.  J Clin Endocrinol Metab. 1994;  79 657-661
  • 24 Russo D, Tumino S, Arturi F, Vigneri P, Grasso G, Pontecorvi A, Filetti S, Belfiore A. Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma.  J Clin Endocrinol Metab. 1997;  82 3906-3908
  • 25 Schwab KO, Gerlich M, Broeker M, Sohlemann P, Derwahl M, Lohse MJ. Constitutively active germline mutation of the thyrotropin receptor gene as a cause of congenital hyperthyroidism.  J Pediatr. 1997;  131 899-904
  • 26 Tonacchera M, Agretti P, Rosellini V, Ceccarini G, Perri A, Zampolli M, Longhi R, Larizza D, Pinchera A, Vitti P, Chiovato L. Sporadic nonautoimmune congenital hyperthyroidism due to a strong activating mutation of the thyrotropin receptor gene.  Thyroid. 2000;  10 859-863
  • 27 Trulzsch B, Krohn K, Wonerow P, Chey S, Holzapfel HP, Ackermann F, Fuhrer D, Paschke R. Detection of thyroid-stimulating hormone receptor and Gsalpha mutations: in 75 toxic thyroid nodules by denaturing gradient gel electrophoresis.  J Mol Med. 2001;  78 684-691
  • 28 Wonerow P, Chey S, Fuhrer D, Holzapfel HP, Paschke R. Functional characterization of five constitutively activating thyrotrophin receptor mutations.  Clin Endocrinol (Oxf). 2000;  53 461-468

Correspondence

Prof. Dr. med. R. Paschke

Universität Leipzig

Zentrum für Innere Medizin

Medizinische Klinik und Poliklinik III

Philipp-Rosenthal-Str. 27

04103 Leipzig

Germany

Phone: +49/341/97 13 20 0

Fax: +49/341/97 13 20 9

Email: pasr@medizin.uni-leipzig.de

    >